Nuclear medicine therapy using
radiopharmaceuticals
The emerging division of
radiology that examines organ function and structure using highly tiny
quantities of radioactive materials, called radiopharmaceuticals, is known as
nuclear medicines. In
nuclear medicine studies, radiopharmaceuticals are delivered orally or intravenously to the patient (Czernin et
al., 2019). Patients' body areas or organ systems being
studied become radioactive for a minute. The radiations (mainly gamma
rays) are emitted from a specific body part and can be detected and analyzed
using a gamma camera.
Targeted body parts absorb radiopharmaceuticals.
These are also known as a radionuclide or radioactive tracers. There are
several types of radionuclides accessible. These tracers are the foundation of
nuclear medicine. The type of radionuclide utilized will be determined by
the study and the bodily part under investigation.
The alpha, beta, or gamma
rays are emitted during their radioactive decay. Gamma emitters are,
therefore, the ideal radiotracers. Gamma rays are low ionizers that are also
penetrative enough to be detected outside the body. Nuclear medicine enhances their
radioactivity for a short period.
Technetium 99m is the most
widely utilized radioelement. It allows for the investigation of many bodily
areas and emits gamma rays solely, making it suited to gamma-camera detectors.
These elements include thallium, iodine, technetium, gallium, and xenon in
various forms. Potassium-40
and carbon-14 are present in all living objects.
Patients preparation for nuclear medicine
procedures
A limited quantity of
radioisotope is given to the patient, either orally or intravenously, to
increase the visibility of specific organs or vascular structures during a
nuclear medicine test. And once the radiotracer has reached the part of the body being studied, the
radiologist puts a gamma detector camera near the site and starts the scanning
procedure. The images are visulize on a computer screen (Yordanova et al., 2017).
Advantages and limitations of nuclear medicine
There may be certain following limitations of
nuclear medicine ;
·
Rare allergic reactions
·
Radiation risk
·
Ionizing radiation imaging of pregnant
mothers is typically avoided if at all feasible.
· Breast-feeding and close contact with the
child might need to be restricted. Because radiation can pass to the baby.
There
are many benefits of nuclear medicine. It helps the doctor to evaluate the
functioning of a particular body organ. Effects of injury, disease, or infection
are studied in this way.
Ailments
diagnosed via nuclear medicine procedures.
Different types of cancers,
hyperthyroidism, thyroid cancer, lymphomas, and myelomas, are detected by this
therapy. The particular scan is performed for a special part (Velleman et al., 2021). Renal scans ( for
kidneys), thyroid, bone, gallium, heart, brain, and breast
scans are performed. Mammograms are used to locate cancerous areas in the
breast.
Three
applications of nuclear medicine to Positron Emission Tomography
Positron emission tomography (PET) uses a minor amount of
radioisotope, a specific camera, and a computer to analyze the functioning of
targeted tissues and organs. It can detect illness at an early stage by detecting
alterations at the cellular level.
It is also called PET
imaging or a scan, a type of nuclear medicine imaging. It accurately analyzes
essential body functions such as metabolism. PET can detect the functioning of
tissue and organ (Agostinelli et al., 2016). Doctors perform PET
scans to:
·
diagnosis
cancer
·
determines
cancer spreads.
·
determine
the effects of myocardial infarction on heart muscles
·
assess
if some regions of the heart muscle may improve from angioplasty or heart surgery.
· Brain
abnormalities such as tumors, memory problems, seizures, and other central
nervous system diseases are studied.
· To
diagnose dementias, different genetic disorders such as Alzheimer's disease, and
cerebrovascular accident (stroke)
·
Specific
surgical sites of the brain are located before surgery.
References
Agostinelli, C.,
Gallamini, A., Stracqualursi, L., Agati, P., Tripodo, C., Fuligni, F., Sista,
M. T., Fanti, S., Biggi, A., & Vitolo, U. J. T. L. H. (2016). The combined
role of biomarkers and interim PET scan in predicting treatment outcome in
classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort
study. 3(10), e467-e479.
Czernin,
J., Sonni, I., Razmaria, A., & Calais, J. J. J. o. N. M. (2019). The future
of nuclear medicine as an independent specialty. 60(Supplement 2), 3S-12S.
Velleman,
T., Noordzij, W., Dierckx, R. A., Ongena, Y., & Kwee, T. C. J. J. o. N. M.
(2021). The new integrated nuclear medicine and radiology residency program in
the Netherlands: why do residents choose to subspecialize in atomic medicine
and why not? , 62(7), 905-909.
Yordanova, A., Eppard, E., Kürpig, S., Bundschuh, R.
A., Schönberger, S., Gonzalez-Carmona, M., Feldmann, G., Ahmadzadehfar, H.,
Essler, M. J. O., & therapy. (2017). Theranostics in nuclear medicine
practice. 10, 4821.
0 Comments